Amino acid residues critical for anaplastic lymphoma kinase receptor cleavage by Shetty, Kunal
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2015
Amino acid residues critical for
anaplastic lymphoma kinase
receptor cleavage
https://hdl.handle.net/2144/16272
Boston University
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
AMINO ACID RESIDUES CRITICAL FOR ANAPLASTIC 
 
LYMPHOMA KINASE RECEPTOR CLEAVAGE 
 
 
 
 
by 
 
 
 
 
KUNAL R. SHETTY 
 
B.A., Colgate University, 2011 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Arts 
 
2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 © 2015 by 
  KUNAL R. SHETTY 
  All rights reserved 
Approved by 
 
 
 
 
First Reader   
 J. Fernando Garcia-Diaz, Ph.D. 
 Professor of Physiology  
 
Second Reader   
 Hao Huang, Ph.D. 
 Research Fellow, Dana Farber Cancer Institute 
 
  
 
 
 
 
 
 
 
 
 
 
 iv
ACKNOWLEDGMENTS  
 
 
I would like to thank Dr. Rani George and research fellow Dr. Hao Huang for their 
guidance on this project. I would also like to acknowledge the members of the George 
Lab for their contributions.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 v
AMINO ACID RESIDUES CRITICAL FOR ANAPLASTIC LYMPHOMA 
KINASE RECEPTOR CLEAVAGE 
KUNAL R. SHETTY 
 
ABSTRACT 
 The overexpression and phosphorylation of the wild type Anaplastic Lymphoma 
Kinase (ALK) receptor in neuroblastoma has been associated with a worse prognosis for 
patients suffering from high risk neuroblastoma. Recent evidence has shown that 
truncated forms of the ALK receptor may be capable of promoting downstream pathways 
associated with ALK activation and increased cellular proliferation. ALK has been shown 
to cleave into 220kDa and 140kDa bands in vivo, but the exact location of the cleavage 
site within the ALK protein has not yet been characterized. By generating amino acid 
substitutions around the putative cleavage site of ALK, we sought to determine if we 
could inhibit ALK cleavage. We were able to significantly inhibit cleavage through 
substitutions in amino acids L655 and F656 surrounding our predicted cleavage site.  
These amino acids may potentially play a critical role in enzymatic identification of the 
ALK cleavage site and mediating ALK cleavage. Future studies are necessary in order to 
determine if ALK constructs with three amino acid substitutions around the cleavage site 
will show complete ALK cleavage inhibition and determine the relationship between 
ALK cleavage and activation of downstream pathways.  
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INTRODUCTION 
Neuroblastoma 
Neuroblastoma is the most common extracranial cancer in childhood and 
accounts for over ten percent of pediatric oncology deaths (Maris 2010). The 
disease predominantly presents itself in infants and young children, with a median 
age of diagnosis of 17 months (London 2005). Patients with higher risk 
neuroblastoma have a five year survival rate of around 40% and over half relapse 
after clinical treatment (Maris 2010).  
The tumor is predominantly derived from neural crest cells of sympatho 
adrenal lineage and has a variable prognosis depending on various risk factors 
(Linet 1999). Neuroblastoma is responsible for a high degree of morbidity and 
mortality, but is also associated with spontanteous regression in some 
circumstances (Carlsen 1990). Neuroblastoma can be acquired both through 
genetic causes as well as somatically in up to 15% of cases (Mosse 2008). An 
older age of onset, overexpression of the MYCN gene and/or the ALK receptor, 
and unfavorable location(s) of gain of function mutations all indicate a poorer 
prognosis (Maris 2010).  
Recent clinical trials have tended to reduce therapeutic intervention for 
patients with non high risk neuroblastoma (Irwin 2015). Treatment of high risk 
neuroblastoma generally involves much more aggressive treatment regimens, 
including surgery, radiation, chemotherapy, myeloablative and immunotherapies. 
Currently, no proven targeted curative agent exists for high risk cases, but 
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relatively recent preclinical research has uncovered the anaplastic lymphoma 
kinase (ALK) receptor as an effective target for the treatment of neuroblastoma 
(Mosse 2009). Research on the ALK receptor in neuroblastoma has led to the 
development of next generation small molecule inhibitors.  
Anaplastic Lymphoma Kinase Receptor 
The Anaplastic Lymphoma Kinase (ALK) is a tyrosine kinase receptor 
(RTK), part of the insulin receptor family that was first characterized in 1994 
through the discovery of the nucleophosmin NPM-ALK fusion protein, which has 
a constitutively activated kinase domain which is thought to contribute to human 
cancers including neuroblastoma, inflammatory myofibroblastic tumour (IMT), 
non small cell lung cancer (NSCLC), and anaplastic large cell lymphoma (ALCL) 
(Morris 1994; Soda 2007). There have been over 22 different genes that have 
been translocated to ALK with several different breakpoint variants with a range 
of downstream effectors and phenotypical expressions (Hallberg 2013). 
Additionally, ALK receptor activation can be caused by ALK amplification, 
overexpression, and point mutations in the kinase domain (Kruczynski 2012). 
Multiple different mechanisms can promote ALK oncogenicity and ALK 
tumourigenic potential exists in a broad range of tissues (Figure 1). 
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Figure 1: ALK Receptor Dysregulation  
The ALK receptor is dysfunctional in various different cancers through overexpression, 
formation of fusion proteins, and ALK point mutations. Point mutations in the ALK 
kinase domain have been a driving mechanism for neuroblastoma tumor formation.  
(Image taken from Hallberg 2013). 
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ALK receptor expression in humans is thought to be high in the nervous 
system during embryogenesis and is theorized to predominantly play a role in 
neuronal development and function during this period (Wellstein 2012). ALK 
mRNA and protein levels have been shown to universally diminish in tissues after 
birth and reach their minimum levels after 3 weeks, and are observed only at 
minimal levels in adult rats (Iwahara 1997). ALK’s physiological role in adult 
humans is not well defined, but from studies showing higher levels of ALK 
mRNA in damaged neurons, it is thought that the receptor plays a role in repair of 
neuronal damage. Alternate studies using a mice model have shown that double 
knockout ALK-/- Ltk-/- mice are viable with no discernible differences in 
function (Weiss 2012).   
Putative ligands for ALK receptor activation have been shown to be 
pleiotrophin (PTN) and midkine (MK) in rodent models, but the physiological 
ligands in humans are still not fully characterized (Stoica 2001; Bowden 2002). 
ALK signaling pathways have predominantly been characterized in oncogenic 
fusion protein pathways such as that with the NPM-ALK and EML4-ALK 
chimeras, in addition to studies with other multiple mutated forms of ALK. ALK 
activates multiple pathways including, but not limited to the RAS-ERK, PI3-
AKT, mTOR, MAPK, and JAK STAT pathways (Mosse 2009; Palmer 2009). 
These pathways predominantly regulate cell growth, differentiation, anti-
apoptotic signaling, and cellular proliferation.   
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The ALK gene encodes a receptor that is 1620 amino acids and is seen at 
220 kDa on SDS/PAGE gels (Morris 1997; Iwahara 1997). The ALK receptor 
possesses the classic structure of a tyrosine kinase receptor, with an extracellular 
portion, a hydrophobic transmembrane segment, in addition to an intracellular 
kinase domain (Figure 2).The ALK protein extracellular domain contains a 
glycine-rich region in addition to LDLa and MAM domains and shares significant 
homology with leukocyte tyrosine kinase (Duyster 2001; Hallberg 2013). These 
MAM domains are 160 amino acids each and contain cysteines which are 
hypothesized to form disulfide bridges and facilitate cell to cell interactions 
(Morris 1997).The ALK intracellular domain contains a three-tyrosine motif 
YxxxY (Tyr1278, Tyr1282, and Tyr1283), which is located in the activation loop 
of the kinase domain and is thought to undergo sequential autophosphorylation to 
drive kinase activity (Donella-Deana 2005).  
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Figure 2: Structure of the ALK Receptor.  The ALK protein contains an 
extracellular domain (residues 19-1038), a transmembrane segment (residues 
1039-1059), in addition to an intracellular domain (1060-1620). The extracellular 
portion is generally N-glycosylated and consists of N-terminal signal peptide 
(residues 1-18), two MAM domains (264-427 and 480-626), an LDLa domain 
(453-471), and a glycine rich segment (819-940). The intracellular kinase domain 
(residues 1116-1392) is located near the carboxy terminus of the ALK protein 
(Figure taken from Roskoski, 2012). 
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ALK Receptor in Neuroblastoma 
 Currently, it is thought that mutations in the ALK oncogene that cause 
constitutive activation of the tyrosine kinase domain are responsible for the 
majority of cases of hereditary neuroblastoma (Maris 2010). Additionally, this 
hereditary component along with somatic ALK mutations accounts for up to 15% 
of newly diagnosed neuroblastomas. However, the non-mutated and non-
amplified ALK receptor is overexpressed in 90% of neuroblastomas and in 60% 
of these cases it is phosphorylated with high expression levels associated with a 
worse prognosis (Lamant 2000; Palmer 2009; Passoni 2009). 
ALK cleavage is well established and has been shown to occur in the 
rodent brain, where the 220 kDa receptor is proteolytically cleaved into a shorter 
140 kDa fragment (Moog-Lutz 2005; Degoutin 2009). Interestingly, this cleavage 
was not observed in DRG neurons, perhaps due to a secreted factor produced by 
Schwann cells. ALK cleavage has also been expressed in human primary 
neuroblastoma tumors and various neuroblastoma cell lines in both its 220 kDa 
and 140 kDa isoforms, with an 80 kDa fragment recognized by antibodies 
directed to the N terminus recovered from conditioned media of cells expressing 
full length ALK (Iwahara 1994; George RE 2008). In activated ALK tumors, both 
forms of the receptor are phosphorylated, but abundance of the 140 kDa receptor 
is correlated with a poor prognosis tumor with higher ALK expression (Passoni 
2009). When ALK expression is inhibited, there is a decrease in phosphorylation 
of both isoforms (George 2008).  
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Further research is needed to determine the identity of the ligand(s) that 
cleaves the receptor, the conformation of the active site where cleavage occurs, 
and the overall role of ALK receptor cleavage and phosphorylation in the 
pathogenesis of neuroblastoma.   
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Specific Aims/Objectives 
  The hypothesis of our study is that the extracellular domain 
cleavage of ALK results in a constitutively activated receptor, and that inhibiting 
this cleavage could potentially inhibit ALK initiated growth and survival. In order 
to test this hypothesis, we first need to determine the functional significance of 
ALK receptor cleavage in neuroblastoma. The objective of the ALK cleavage 
study is to discover which amino acids are critical in permitting cleavage of the 
ALK receptor. By inhibiting cleavage, it is possible that the ALK protein kinase 
domain will not be activated and the downstream intracellular cascades that lead 
to cell proliferation and differentiation will be inhibited. Through 
experimentation, we hope to further elucidate the functional significance of ALK 
cleavage in neuroblastoma. Specifically, the study will attempt to answer the 
following questions: 
1) Which amino acids are critical in the cleavage of the ALK receptor? 
2) Which amino acids are not critical in the cleavage of the ALK receptor? 
3) Is the amino acid sequence surrounding our predicted cleavage site critical 
to ALK cleavage? 
4) Does ALK cleavage affect ALK phosphorylation? 
 
 Because ALK cleavage may be a primary driver of subsequent 
phosphorylation of activating pathways that lead to cell proliferation and 
metastasis, it is of great necessity that we look into the structural elements that 
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could facilitate this cleavage. By identifying amino acids that are critical to 
ALK cleavage, it will then be possible to obtain insight into the active domain 
of the ALK cleavage site and eventually create an ALK construct resistant to 
cleavage to test in an vivo model. In the future, these results will be important to 
prove that inhibition of ALK cleavage can be leveraged therapeutically to 
induce death of neuroblastoma cells.  
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METHODS 
PCR Amplification and Transformation 
Designed primers for ALK mutation were purchased from Eurofins Scientific and 
were diluted to a standard 25 uM concentration in preparation for PCR. Site directed 
mutagenesis was utilized to acquire copies of mutant ALK cDNA using the QuikChange 
II XL Site-Directed Mutagenesis Kit (Agilent Technologies) closely adhering to the 
manufacturer’s protocol (Figure 3). To 50µL reaction, 25mM forward primer, 25mM 
reverse primer, 5µL  10x reaction buffer, 3 µL Quicksolution, 1 µL dNTP mix, 20 ng/µL 
DNA template, 38 µL distilled water, and 1 µL of 2.5U/μL Ultra HF DNA Polymerase 
were added to RNAse free 1.5 mL microfuge tubes (Ambion).  Each set of mutations in 
the ALK cleavage domain was PCR-amplified using a C1000 Thermal Cycler (BioRad) 
with protocol MBA21 (Table 1). After the PCR reaction, 1μL of 10U/μL Dpn I was 
added to each PCR tube to digest remaining template DNA and the tubes were then 
placed at 37°C for 60 minutes. While digestion occurred, 30 μL XL10-Gold 
ultracompetent cells were placed in a 14ml BD round bottom propylene tubes (Falcon) 
and 1.4 μL of XL10-Gold β-mercaptoethanol was added to the cells and the reaction 
mixture was allowed to incubate on ice for 30 minutes. Then, 2 μL of the Dpn I treated 
DNA was added to each 14mL tube and the reaction was allowed to incubate on ice for 
30 minutes. After incubation, the tubes were heat-pulsed for 30 seconds in a 42°C water 
bath and placed in ice for 2 minutes. 1 mL of Super Optimal Broth with Catabolite 
repression (S.O.C.) Medium was added to each tube and they were incubated at 37°C for 
one hour with shaking at 225 rpm. After shaking, the transformation reaction was 
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transferred to 1.5 mL centrifuge tubes and centrifuged at 3000 rcf using a 5415R 
centrifuge (Eppendorf) for 4 minutes. 700 μL of supernatant were removed and the cells 
were resuspended in solution. The solution was then aliquotted onto Lysogeny 
Broth(LB)/Ampicillin agar 100 mm plates and incubated at 37°C for colony formation.  
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Figure 3: Quikchange Site Directed Mutagenesis Method 
Site directed mutagenesis protocol was utilized in order to obtain ALK mutant plasmid 
constructs. (Image taken from Agilent Technologies website   
http://www.genomics.agilent.com/article.jsp?pageId=388&_requestid=33763).  
 
 
 
 
 
 14 
Plasmid Purification/ Transfection 
Colonies were isolated from plates and transferred to 14 ml round bottom 
propylene tubes (Falcon) containing 5mL of LB media with 5 μL of 100 mg/mL 
Ampicillin and allowed to incubate for 24 hours (Double and triple mutants were 
incubated up to 48 hours to allow for cell growth). Plasmids were purified using QIAprep 
Spin Miniprep Kit (QIAGEN) according to the manufacturer’s protocol. In order to elute 
the plasmid, 25 uL of distilled water was used instead of PE buffer for final step. Plasmid 
concentration was then measured using a 2000 UV-Vis Spectrophotometer (NanoDrop) 
and sent in for sequencing analysis to ensure accuracy through GENEWIZ. 
Two days prior to plasmid transfection, 293 T cells were seeded at .5 x 105 
cells/mL into multiwell  6 plates (Falcon) with 2 mL Dulbecco’s Modified Eagle Medium 
(Gibco) per well and were allowed to incubate at 37°C for 48 hours. The plasmids were 
then transfected into 293T cells using TransIT-LT1 Transfection Reagent (Mirus) 
protocol adding 1 μg of 1μg/ml stock and incubated in a 37°C incubator for 48 hours. 
 
Protein Extraction and Western Blot Analysis 
In order to extract protein  from 293T cells, Nonidet P-40 (NP40) buffer 
consisting of 150mM sodium chloride, 1% NP40, and 50mM Tris, pH 8.0 was used in 
addition to sodium orthovanadate, phosphatase inhibitor (Roche), and a proteinase 
inhibitor (Roche). The BioRad DC Protein Assay was utilized in order to quantify protein 
concentration along with a Bovine Serum Albumin Standard. Approximately 25 µg of 
protein were added to each well and 10x Sample Reducing Agent (NuPAGE) and 4x 
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LDS Sample Buffer (NuPAGE) were added to each sample. The samples were then 
heated for 10 minutes at 70°C and centrifuged briefly. Samples were then loaded onto 
1.5mm x 10 or 15 well 4-12% BisTris  Gel (NuPAGE) with 20 x MOPS-SDS Running 
Buffer containing  1M Tris, 2% SDS, 20 mM EDTA, pH 7.7±0.1. The gel was then run at 
150V for 60 minutes. The gel was then transferred to a 0.45µm nitrocellulose membrane 
using a 10x transfer buffer containing .25 M Tris, 1.92M glycine, pH 8.4 ±0.2, and 10% 
methanol using a voltage of 100V for 90 minutes. 5% milk TBST (25 mM Tris, 0.15M 
NaCl, 5% milk, 0.05% Tween-20, pH 7.5) was then added to membranes where ALK/β-
actin antibodies would be added and 5% BSA-TBST solution (25mM Tris, 0.15M NaCl, 
5% BSA, 0.05% Tween-20, pH 7.5) was added to membranes where p-ALK antibody 
would be added and the membrane blots were blocked for 30 minutes. Primary antibody 
was then added and the membranes were rocked at 4°C overnight. The following day, the 
blots were washed 3 times for 15 minutes with TBST buffer. 5% milk TBST was then 
added to the membranes and secondary antibody was added and the blots were rocked for 
60 minutes at room temperature. The blots were then washed with TBST buffer 3 times 
for 15 minutes to remove any excess secondary antibody. SuperSignal West Pico 
Chemiluminescent Substrate (ThermoScientific) was added in a 1:1 ratio to the ALK/ β-
actin membranes for 7 minutes and SuperSignal West Dura Chemiluminescent Substrate 
(ThermoScientific) was added in a 1:1 ratio to p-ALK membranes for 4 minutes. The blot 
was then imaged in a dark room using an M6B X-O Mat Processor.  
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Antibodies and Cell Culture Conditions 
Primary rabbit mAb antibodies were ALK C26G7 (Cell Signaling, Cat #3333, 1:1000), 
phosphoALK y1604 (Cell Signaling, Cat # 3341, 1:500), and beta-Actin (Cell Signaling, 
Cat #4970, 1:1000). 
Secondary antibody used was goat anti-rabbit IgG-conjugated HRP antibody (Santa-
Cruz, Cat#sc-2054, 1:5000).  
293T cells were cultured in Dulbecco’s Modified Eagle Medium (Gibco) with 10% FBS 
and 1% S/P. Cell Seeding was carried out using Dulbecco’s Phosphate Buffered Saline 
Solution (DPBS) (Gibco) and Trypsin EDTA (Corning).  
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Table 1: MBA 21 Polymerase Chain Reaction Protocol 
The following parameters were input in order to amplify mutant plasmids. 
 
Steps Time  
(minutes: seconds) 
Temperature (ºC)  
1: DNA Denaturation 1:00 95 1 x 
2: DNA Denaturation :50 95  
18x 3: Primer Annealing :50 57.5 
4: Extension 14:00 68 
5: GO TO 2  
6: Final Extension 7:00 68 1x 
7: Hold Forever 12 - 
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RESULTS 
The suspected cleavage site of the ALK protein was predicted based on previous 
mass spectroscopy data from the George lab. The entire ALK genomic sequence has been 
characterized by previous research in the George Lab and the location of the putative 
cleavage site is known (Figure 4).  
Missense mutations were used to alter amino acids surrounding the proposed 
active site. The corresponding notation we used to denote our transformations was 
identity of original amino acid: amino acid primary location in ALK protein: New 
identity of amino acid. For example, A649W indicates we changed the original alanine 
(A) at the 649 amino acid position into tryptophan (W). We used various forward and 
reverse primers and mutated constructs to create a total of 24 different unique constructs 
of the ALK protein that we then tested for cleavage (Figures 6-8,10,12,14,16; Table 2). 
We then tested many of the promising constructs that had some degree of inhibition of 
cleavage for ALK phosphorylation (9,11,13,15; Table 3).   
In order to test for cleavage, both positive and negative controls were utilized. 
The positive control was cleavable wild type ALK protein and the negative control was 
an uncleavable ALK construct that had a deleted 65 amino acid sequence after the 
MAM2 domain where our putative cleavage site is expected to be located (Figure 5). 
Both of these constructs were generated in the George Lab.  
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Figure 4: Putative ALK Cleavage site 
The predicted cleavage site of ALK was determined by mass spectroscopy data (Arrow 
points to the cleavage site between asparagine at position 654 and leucine at position 
655). The surrounding amino acids were mutated and inhibition of cleavage was tested. 
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Figure 5: Wild-type ALK and ALK MAM2 #5  
In order to test mutant ALK constructs for cleavage, wild type ALK was used as the 
positive control and ALK MAM2 #5 was used as the negative control. ALK WT is 
cleaved into a 80 kDa band [not shown] and a 140 kDA band in addition to the full length 
220 kDa band. The ALK MAM2 construct has a deleted amino acid region after the 
MAM2 domain and gives a 220 kDa band, but does not cleave to give a 140 kDa remnant 
band. 
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Figure 6: ALK Cleavage Results 
The S652D, R653E, L655K, and P671A mutants also display partial inhibition of ALK 
cleavage. ALK cleavage may potentially be partially inhibited by mutations in close 
proximity to the N-terminus side of the putative cleavage site.  
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Figure 7: ALK Cleavage Results 
ALK cleavage was not observed in the ALK R658E mutant or in the E657W/F656D and 
the N654E/F656D mutants. ALK can be partially inhibited by L655K mutant, but is 
unaffected by double mutants, which include the F656D double mutation constructs. 
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Figure 8: ALK Cleavage Results 
ALK cleavage wasn’t inhibited by the E657W and T648D mutants, but can be inhibited 
by the L655K/F656D mutant. Additionally, the ALK N659D/P1374T mutant inhibits 
ALK cleavage (See Discussion).* 
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Figure 9: ALK Phosphorylation Expression 
 
Although ALK cleavage was inhibited by the L655K/F656D mutant, ALK 
phosphorylation was still observed. Additionally, the ALK N659D/P1374T mutant 
inhibits ALK cleavage and ALK phosphorylation (See Discussion).* 
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Figure 10: ALK Cleavage Results 
ALK cleavage is not inhibited by the P675A mutation. 
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Figure 11: ALK Phosphorylation Expression 
 
ALK phosphorylation is seen in the P675A mutation. 
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Figure 12: ALK Cleavage Results 
 
ALK cleavage is not inhibited by mutations at the P675A, N654D, F677D, A649W, and 
N659D positions. ALK cleavage is partially inhibited by mutation at N654D position.  
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Figure 13: ALK Phosphorylation Expression 
 
Activation of pALK was observed in all of the mutants. 
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Figure 14: ALK Cleavage Results  
ALK cleavage is not inhibited by the N647F mutation. 
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Figure 15: ALK Phosphorylation Expression 
 
ALK phosphorylation is seen in the P675A mutation. 
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Figure 16: ALK Cleavage Results 
The ALK L654Q/ F656D and N654K/L655R/F656D triple mutants may inhibit cleavage. 
This will need to be retested in future to confirm to ensure cleavage occurs and check for 
ALK phosphorylation. 
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Table 2: ALK Cleavage Final Results (Duplicates/Previous Cleavage Tests shown) 
ALK mutations in amino acids L655 and F656 immediately surrounding the cleavage site 
of the ALK receptor showed the greatest inhibition of cleavage. The double mutant 
L655K/F656D showed almost complete inhibition of cleavage.  
 
Negative control 
(MAM 5#)  
+++++  
(No cleavage)  
       
Positive control 
(wtALK)  
/ 
(Strong 
Cleavage)  
       
N647F  /         
T648D  /         
A649W  /  /      
P650A  /         
S652D  +         
R653E  ++         
N654D  ++  ++      
L655K  ++  +++      
F656D  +++         
E657W  /  /  / / 
R658E  /         
N659D/ P1374T*  ++++  ++++  ++++   
N659D  /  /  / / 
L664D  /         
P671A  /         
P675A  /  /  /   
F677D  /  /  /   
P679A  /         
L684D  /         
             
F656D/E657W  /         
N654E/F656D  /         
L655K/F656D  ++++  ++++  +++   
L655Q/F656D  ++++   ?   ?  
             
N654K/L655R/F656D ++++   ?   ?  
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Table 3: pALK Expression Results (Duplicates shown) 
The N659D/P1374T mutant showed complete inhibition of pALK. The double mutant 
L655K/F656D showed decreased levels of pALK.  
 
p-ALK  Negative 
control 
(MAM 5#)  
NNNN 
(No 
phosphorylation) 
   Positive 
control 
(wtALK)  
Y 
(Strong 
phosphorylation)  
N647F  Y     
T648D  Y     
A649W  Y  Y  
P650A        
S652D        
R653E        
N654D  NN  N  
L655K       
F656D        
E657W  Y  Y  
R658E        
N659DP1374T  NNNN  NNNN  
N659D  Y     
L664D        
P671A        
P675A  Y  YY  
F677D  Y  Y  
P679A        
L684D        
         
F656D/E657W        
N654E/F656D        
L655D/F656D  NNN  NNN  
L655Q/F656D    ?   ? 
         
N654K/L655R/F656D   ?   ? 
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DISCUSSION 
 
 In transforming the identity of our amino acids, we aimed to change the size or 
polarity of the amino acid(s) for the purpose of interfering with the enzyme recognition of 
the active site of cleavage. This methodology has been utilized in previous research 
aimed at preventing enzymatic recognition of cleavage sites and inhibiting protein 
cleavage (Mercuri et al 2000; Kim et al 2012). Significant inhibition of cleavage was 
seen predominantly when mutating leucine at the 655 position to lysine, phenylaline at 
the 656 position to aspartic acid, and in the mutant where both of these amino acids were 
substituted. These results indicate that the hydrophobic amino acids adjacent to the ALK 
cleavage site may play a critical role in enzymatic recognition. Further structural data will 
necessary in determining how the structure of this region is affected by altering of these 
amino acids.  
Additionally, we found that the ALK N659D/ P1374T mutant could completely 
inhibit cleavage and subsequent ALK activation. The mutation of proline at the 1374 
position to threonine was found when the N659D mutant was sequenced and was a 
secondary mutation that may have occurred as a result of an elongation error by DNA 
polymerase. This mutation was in the tyrosine kinase domain of ALK, and most likely 
interrupted the secondary structure of the protein and potentially prevented normal ALK 
processing and activation. The single mutant N659D did not inhibit cleavage and showed 
ALK phosphorylation.  
Unfortunately, there is not enough evidence to prove that inhibition of ALK 
cleavage could correlate with reduction in the phosphorylation of ALK. More data will 
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need to be collected in order to further elucidate if a relationship exists between ALK 
cleavage and activation. 
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CONCLUSION 
Although inhibition of cleavage of ALK with prevention of associated activation 
with single and double mutants was unsuccessful, it will be important to test if triple 
mutant constructs with amino acid substitutions adjacent to our putative cleavage site will 
be able to fully inhibit cleavage and affect ALK phosphorylation.   
If we acquire an ALK cleavage resistant mutant that prevents ALK activation, it 
will then be possible to test whether inhibition of ALK can be leveraged therapeutically 
to induce death of NB cells in vitro and then eventually in an in vivo model. 
  
 37 
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